Breaking News, Promotions & Moves

Catalent Names Matti Masanovich Senior Vice President & CFO

Masanovich will have responsibility for all aspects of Catalent’s global financial operations and will be a member of the executive leadership team.

Catalent, Inc. has appointed Matti Masanovich as senior vice president and chief financial officer, effective July 5, 2023.

Masanovich will have responsibility for all aspects of Catalent’s global financial operations, including financial planning and analysis, controllership, public reporting and investor relations, capital markets activities, bill payment and collection, tax, and treasury. He will also be a member of Catalent’s executive leadership team.

Prior to joining Catalent, Masanovich served as executive vice president and CFO of Tenneco Automotive until it was acquired by Apollo. Previously he was CFO at Superior Industries International and General Cable Corp. Earlier in his career, Masanovich held finance leadership roles of increasing responsibility in a number of companies in the automotive industry, where he demonstrated a strong history of improvement and profitability and operating efficiency. Masanovich began his career with PricewaterhouseCoopers LLP.

“Matti is a proven finance leader whose deep experience growing and driving profitability at publicly traded, complex global manufacturing companies is ideally suited to help Catalent reach its next level of performance, including enhanced profitability and value-creation for shareholders,” said Alessandro Maselli, President, and CEO of Catalent. “He brings significant expertise and a highly strategic approach that I am confident will make him an invaluable addition to Catalent’s executive leadership team as we continue to seize opportunities in the CDMO space.”

“Catalent is a dynamic company that operates in a critical, fast-growing sector that has a meaningful impact on helping people live longer, healthier lives,” said Masanovich. “I am impressed with their portfolio of solutions and feel the company has the right capabilities to serve that market, and I am excited to work with Catalent’s talented team to create value for its customers, patients, and shareholders.”


Keep Up With Our Content. Subscribe To Contract Pharma Newsletters